Immunotherapy

May 16, 2017

Provenge Immunotherapy Increases Overall Survival in African-American Men with Metastatic Prostate Cancer

News

African-American men with metastatic castrate-resistant prostate cancer survive significantly longer than Caucasian men when treated with Provenge, according to new findings from Dendreon’s PROCEED registry, which is following patients’ outcomes in a ... Read more

January 5, 2017

Results of Phase 3 Study of Immunotherapy Prostvac for Advanced Prostate Cancer Due at Year’s End

News

Bavarian Nordic announced that full data from its Phase 3 study assessing the effectiveness of its immunotherapy candidate, Prostvac, to improve survival in people with metastatic castration-resistant prostate cancer (mCRPC) is now expected late in ... Read more

July 20, 2016July 20, 2016

Advanced Prostate Cancer Patients May Respond Well to Keytruda Immunotherapy, According to Study

News

Immunotherapy with pembrolizumab, an antibody that blocks PD-1 signaling, may also work for advanced-stage prostate cancer, according to a preliminary study conducted by researchers at Oregon Health and Science University ... Read more

April 12, 2016April 12, 2016

Androgen Deprivation Therapy in Prostate Cancer May Counter Immunotherapy, Raising Risk of Relapse

News

UT Southwestern Medical Center researchers have shown that medical androgen deprivation therapy, commonly used in combination with promising immunotherapies, can actually suppress the immune response and block the efficacy of the immunotherapy. ... Read more

February 16, 2015February 16, 2015

Global Report on 2015 Prostate Cancer Vaccine Pipeline Released

News

The world’s largest market research store, Research & Markets, recently released its annual Global Prostate Cancer Vaccine Clinical Pipeline Insight 2015 Report Highlights. The report covers the following key areas in the ... Read more

November 12, 2014

Maker of Provenge for Prostate Cancer Files for Bankruptcy

News

Seattle-based Dendreon, best known for developing and marketing the first and only approved immunotherapy for prostate cancer, Provenge, has just filed for bankruptcy protection in the wake of the drug’s hugely ... Read more